Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Peijia Medical Limited
沛嘉醫療有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL FOR REGISTRATION APPLICATION OF THE TaurusTrio™ TRANSCATHETER AORTIC VALVE SYSTEM

This announcement is made by Peijia Medical Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on December 11, 2025, the Company received the approval from the National Medical Products Administration of the People's Republic of China (the "**NMPA**") for the registration application of the TaurusTrio™ Transcatheter Aortic Valve ("**TAV**") system (the "**System**").

Reference is made to the Company's announcement dated January 14, 2022. The TaurusTrio™ TAV system is developed and manufactured by the Company based on the exclusive license of Trilogy™ Transcatheter Heart Valve ("**THV**") System obtained from JenaValve Technology, Inc. ("**JenaValve**"). It is designed to treat patients with native symptomatic severe aortic regurgitation ("**AR**") through transfemoral access. Unlike in patients with aortic stenosis, in patients with AR, there is often no calcification for the TAV to anchor onto, leaving AR patients with limited treatment options. The System incorporates proprietary locator technology, which enables secure anchoring by attaching to the native leaflets even in the absence of calcium, while ensuring commissural alignment.

JenaValve's Trilogy™ THV System received CE Mark approval in May 2021 and, as of the date of this announcement, has been used in over 1,000 commercial procedures in real-world clinical practice. The Company looks forward to the successful launch of TaurusTrio™ TAV system in China, which is expected to address a significant unmet need by providing a safe and effective treatment option for Chinese patients suffering from severe AR.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET TaurusTrio™ TAV SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, December 11, 2025

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP, Mr. Huacheng WEI as independent non-executive Directors.